Background: Recently, the importance of quality assurance (QA) for cancer screening has gained increasing attention in Japan. This study aimed to evaluate QA process indicators for populationbased colorectal cancer screening during 2003-13. Methods: A national cancer screening database was used to evaluate the following process indicators: the positivity rate, diagnostic follow-up rate, unidentified results rate, non-compliance with diagnostic follow-up rate, cancer detection rate and positive predictive value (PPV). Results: The positivity rate remained constant at 6.5% until 2011, and then increased slightly thereafter. During 2003-13, the cancer detection rate increased from 0.15% to 0.21%, and the PPV increased from 2.2% to 3.1%. Although the diagnostic follow-up rate increased from 58% to 67%, the non-compliance with diagnostic follow-up rate decreased from 24% to 16% and the unidentified results rate decreased from 18% to 17%. Conclusions: During the study period, the QA process indicators for colorectal cancer screening in Japan generally improved. However, the recent increase in the positivity rate requires careful observation. Innovative solutions are needed to increase the diagnostic follow-up rate.
Introduction
Cancer is the leading cause of death in Japan. Accordingly, the targets of the 2007 Basic Cancer Control Plan and its 2012 revision include a 20% reduction in the age-standardized mortality rate (1). Despite the clear importance of an organized cancer screening system in reducing cancer mortality (2) , Japan has seen little progress in the implementation of such a system. An organized screening program requires that all members of the target population are identified and invited to undergo individual screening. However, Japanese municipal screening programs only target individuals who do not undergo screening tests at their workplaces, and workplace-based screening is generally performed in an opportunistic manner. In addition, municipal programs initiated before the start of the Basic Cancer Control Plan lacked quality assurance (QA) systems, another critical component of organized screening. Therefore, those screening programs were of low quality and were unable to reduce cancer mortality.
According to the Organization for Economic Cooperation and Development, Japan has lower rates of colorectal, cervical and breast cancer screening relative to other counties (3) . Accordingly, in 2008, Japan implemented QA activities for municipal cancer screening programs (4) that were based on successful organized screening programs used in European countries (5) . Although appropriate QA indicators are needed to precisely monitor the activities of the screening provider and facility, Japanese programs historically have not included sufficient indicators or even basic monitoring. The Japanese Ministry of Health, Labour and Welfare (MHLW) recently implemented structural checklists and national standards for monitoring short-term screening outcomes using process indicators (6, 7) . Although data regarding these process indicators have been collected since the mid-1980s, checklist data have only been available since 2008. Therefore, it is appropriate to analyze the QA activities launched during or after 2008 and evaluate their effects on the quality of cancer screening in Japan.
In Japan, the colorectal region is a major cancer site, and therefore, colorectal cancer screening comprises an important anti-cancer program. The reported colorectal incidence and mortality rates in Japan per 100 000 individuals, standardized to the world standard population, were 38.1 in 2013 and 11.2 in 2015, respectively, and these values represent the second highest in incidence and thirdhighest in mortality rate burdens among cancers nationwide (8, 9) . The importance of early colorectal cancer detection via screening is clearly demonstrated by the 5-year relative survival rates according to clinical stage in Japan: 97% for local disease, compared to 72% and 16% for regional and distant diseases, respectively (10) .
Municipal screening programs are based on a national guideline issued by the MHLW (11) , and target all asymptomatic residents aged ≥40 years, irrespective of colorectal cancer risk. Eligible residents are offered annual immunochemical fecal occult blood testing (iFOBT) wherein two fecal samples from consecutive days are collected from a self-sample of participants. These samples are submitted immediately to screening facilities (submission by mail is not allowed) and refrigerated until testing. The test results are categorized as positive or negative, according to the cut-off value set at each municipality. Participants who obtain positive results are required to have a diagnostic examination. Colonoscopy is offered as the first choice, with flexible sigmoidoscopy in combination with barium enema X-ray examination as alternatives in case there is an inability to perform a colonoscopy. These screening tests are low-cost or free, and the expenses associated with a diagnostic examination are partially covered by health insurance.
Although municipal governments are responsible for providing population-based cancer screening programs, QA activities are promoted cooperatively within the prefecture by municipalities, screening facilities and medical providers (4) . The screening tests are outsourced to screening facilities that are required to the national guideline and report the screening protocol (e.g. type of iFOBT kit and cut-off values). Medical providers who perform diagnostic examinations are required to return the final reports to municipalities and screening facilities, and each screening facility and municipality are required to evaluate their screening implementation status using checklists and process indicators by themselves. The prefecture then evaluates these data and provides feedback with necessary support or advice to each municipality and screening facility based on the evaluation.
The present study aimed to evaluate trends in the national QA process indicators for municipal colorectal cancer screening programs during 2003-13 based on MHLW data (12) .
Methods
The MHLW maintains a national database of individuals who undergo municipal cancer screening and are subsequently diagnosed with cancer. These data are submitted from each municipality within 2 years after screening for each municipality. Although we abstracted data from 2003 to 2013, the database does not include some information from 2009 corresponding to the area affected by the Great East Japan Earthquake of 2011 (46 municipalities in the Miyagi, Iwate and Fukushima prefectures), as those municipalities were unable to report data in 2011. The affected municipalities accounted for~3% of all Japanese municipalities. The national and prefectural QA process indicators were calculated as shown in Table 1 . As the Basic Cancer Control Plan (2012 revision) aimed to reduce the age-standardized cancer mortality rate among people aged <75 years, the present study targeted individuals aged 40-74 years. Table 2 shows the numbers of 40-74-year-old individuals who underwent municipal colorectal cancer screening according to sex and age group. More than 90% of municipalities performed colorectal cancer screening during 2003-13, and this rate remained constant; however the total number of screening participants increased from 5 401 533 in 2003 to 6 332 978 in 2013. The male:female ratio was~1:1.7, and decreased slightly near the end of the study period. Participants aged ≥60 years accounted for 62% of the participants Positivity rate, cancer detection rate and positive predictive value Figure 1 shows the positivity rates for colorectal cancer, which remained constant at 8-9% among men and 5-6% among women, although a slightly increasing trend was observed in 2013 for both sexes. Figure 2 shows that the detection rate remained unchanged at 0.23% among men and 0.1% among women during 2003-07, and subsequently increased to 0.3% among men and 0.15% among women after 2008. Figure 3 shows the positive predictive value (PPV), which increased from 2.6% to 3.7% among men and from 1.8% to 2.6% among women during 2003-13. A remarkable increasing trend was observed in 2008 for both sexes. These three process indicators had higher values among men, compared to women and among elderly people, compared to middle-aged people.
Results
The rates of diagnostic follow-up, unidentified results and non-compliance with diagnostic follow-up Figure 4 shows the diagnostic follow-up rate, which increased from 55% to 65% among men and from 60% to 69% among women during 2003-2013. A remarkable increasing trend was observed for both Figure 5(a) shows the non-compliance with diagnostic follow-up rate, which decreased from 26% to 17% among men and from 23% to 15% among women during 2003-2013. A remarkable decreasing trend was observed for both sexes in 2008. Figure 5(b) shows the unidentified results rate, which decreased slightly from 18% in 2003 to 16-18% in 2013 for both sexes. A minor decreasing trend was observed for both sexes in 2008. During the study period, the diagnostic follow-up rate was higher among women, compared to men, and among elderly people, compared to middle-aged people. However, lower rates of unidentified results and non-compliance with diagnostic follow-up results were observed among women, compared to men, and among elderly people, compared to middle-aged people.
Discussion
Participation in colorectal cancer screening programs increased, especially among elderly people during 2003-13, which may be partially related to the aging Japanese population. Rapid improvements in some process indicators were observed in 2008. This may be related to reporting omission, as municipalities reported screening results within a few months up to 2007. However, the MHLW subsequently approved an extended submission period, which led to the implementation of two submission periods in 2008. This process allowed for early data reporting during the following year after screening, with more comprehensive data reporting (e.g., the results of further examination) within 2 years after screening.
The 2008 publication of the national standard by the MHLW (4) for the purpose of promoting QA activity in the prefectures may also have contributed to later improvements in process indicators. Briefly, the national standards for acceptable colorectal cancer screening values were set as follows: positivity rate, <7%; cancer detection rate, >0.13%; PPV, >1.9%; diagnostic follow-up rate, >70%; unidentified results rate, <10%; and non-compliance with diagnostic follow-up rate, <20%. Furthermore, the following desirable standard values were set: diagnostic follow-up rate, >90%; unidentified results rate, <5%; and non-compliance with diagnostic follow-up rate, <5%. During 2008-13, the numbers of prefectures that did not meet the acceptable detection rate, PPV, diagnostic follow-up rate and non-compliance with diagnostic follow-up rate values decreased from 17, 12, 40 and 32 to 2, 1, 21 and 13, respectively. These national standard values should be revised more strictly to ensure further improvements in prefectural QA activity.
In this study, we did not evaluate the participation rate, as the target population numbers reported by municipalities appeared to be unreliable. Japanese population-based screening programs target individuals who are not covered by workplace-based cancer screening programs. However, these individuals cannot be correctly identified by municipalities, given the lack of a relevant framework. The establishment of a call-recall system to encourage participation by the real targets of population-based screening is needed, and this framework should be created in the near future. We also did not evaluate severe complications resulting from diagnostic examinations (i.e., death, perforation, hospitalization after colonoscopy) in this study. Although these data have been collected since 2008, the validity has not been investigated. Analysis of these data would be performed in the near future.
Positivity rate, cancer detection rate and positive predictive value During the study period, the colorectal cancer positivity rate remained almost constant (Fig. 1) , whereas rapid increases in the cancer detection rate and PPV were observed in 2008. The extended reporting period may have facilitated the tracking of further examinations and may have contributed to the remarkable increase in the cancer detection rate. However, the recent slight increase in the positivity rate requires careful observation. Although increases were more pronounced among elderly people, these trends were similar among all age groups. The observed differences in colorectal cancer positivity rates may be related to differences in the iFOBT kit (i.e. measurement method and cut-off value) (13, 14) , particularly to improvements in the kit's legibility. Abnormal positivity rates may also be related to the quality control of screening procedures (e.g. maintenance of fecal occult blood detection devices, storage conditions for stool occult blood specimens and technical proficiency of the staff conducting iFOBT). Further efforts should be made to improve the monitoring system by collecting such detailed information, which is currently unavailable. Such QA activities should be performed via prefectural initiatives (4).
Rates of diagnostic follow-up, unidentified results and non-compliance with diagnostic follow-up
The diagnostic follow-up rate increased rapidly during the study period (Fig. 4) , whereas the non-compliance with diagnostic followup and unidentified result rates decreased rapidly in 2008 (Fig. 5) . The extended reporting period apparently contributed to both the remarkable increase in the diagnostic follow-up rate and decrease in the non-compliance rate during 2008-13.
The diagnostic follow-up rate is the most important indicator of a decreasing cancer mortality rate. Although this parameter improved remarkably during the study period, the ideal rate should be very close to 100%; therefore, the current rates of 70% remains inadequate. The 2017 revision of the Basic Cancer Control Plan should prioritize improvements in the diagnostic follow-up rate.
The unidentified result and non-compliance with diagnostic follow-up rates are exclusive indicators that independently address the causes of the low diagnostic follow-up rate (Table 1) . The unidentified result rate indicates that completed examinations are insufficiently tracked. If a medical provider does not return the result of a diagnostic examination, and thus the unidentified result rate is high, the municipality has been encouraged as a part of QA activity to track each participant and solicit the following further details by mail or telephone: the date of examination, name of medical provider, modality of examination and detailed results (4) . Incomplete tracking will result in a case being categorized as an unidentified result. The non-compliance with diagnostic follow-up rate indicates that participants have not been sufficiently reminded to re-schedule a missed follow-up. Therefore , it is important to understand the meaning of each quality indicator, and to use this information to more effectively address each issue. Especially, a high unidentified result rate may lead to an underestimation of the diagnostic follow-up rate and must be reduced immediately.
Conclusion
Our findings strongly suggest that the QA process indicators for colorectal cancer screening have generally improved. However, the recently increase in the positivity rate requires careful observation. Furthermore, innovative solutions are needed to decrease the unidentified result and non-compliance with diagnostic follow-up rates in Japan. These findings address approximately half of the Japanese population, which is covered by population-based screening. As mentioned above, there is no existing framework of QA in workplace-based cancer screening programs; in other words, approximately half of the Japanese population does not participate in effective screening. Therefore, a more comprehensive reporting system to provide clearer information regarding cancer screening in Japan should be developed immediately.
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